{"id":28601,"date":"2020-02-03T09:13:13","date_gmt":"2020-02-03T14:13:13","guid":{"rendered":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/?p=28601"},"modified":"2020-02-03T10:14:37","modified_gmt":"2020-02-03T15:14:37","slug":"codagenix-co-founded-by-fsc-professor-receives-20-million-funding","status":"publish","type":"post","link":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/2020\/02\/03\/codagenix-co-founded-by-fsc-professor-receives-20-million-funding\/","title":{"rendered":"Codagenix, Co-founded by FSC Professor, Receives $20 Million Funding"},"content":{"rendered":"<p>Codagenix, a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, and headed by Dr. J. Robert Coleman, CEO and professor in the Biology department, has closed a $20 million Series B investment to continue development of live attenuated RSV vaccine for the elderly, a broadly-protective influenza vaccine, and an oncolytic virus therapy for triple-negative breast cancer.<\/p>\n<p>The investment was led by Adjuvant Capital, a venture capital firm that incubated at Gates Global Health Initiative, with the participation of other investors, TopSpin Partners and Euclidean Capital.<\/p>\n<p>Codagenix was founded by Dr. Coleman, CSO, Dr. Steffen Mueller, and Stony Brook University Distinguished Professor Eckard Wimmer. The goals of the high-tech start-up are to:<\/p>\n<ul>\n<li>commercialize viral design technology developed by Dr. Wimmer,<\/li>\n<li>answer the unmet need for more effective vaccines, and increased treatment options for cancer.<\/li>\n<\/ul>\n<p>Codagenix has nine employees, and is headquartered at Broad Hollow Bioscience Park, at FSC,<\/p>\n<p>\u201cOur mission is to improve human health by commercializing our technology to make better, more effective vaccines,&#8221; says Dr. Coleman.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Codagenix, a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, and headed by Dr. J. Robert Coleman, CEO and professor in the Biology department, has closed a $20 million Series B investment to continue development of live attenuated RSV vaccine for the elderly, a broadly-protective influenza vaccine, and an oncolytic virus therapy for [&hellip;]<\/p>\n","protected":false},"author":30,"featured_media":28720,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[22],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/posts\/28601"}],"collection":[{"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/comments?post=28601"}],"version-history":[{"count":13,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/posts\/28601\/revisions"}],"predecessor-version":[{"id":28709,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/posts\/28601\/revisions\/28709"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/media\/28720"}],"wp:attachment":[{"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/media?parent=28601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/categories?post=28601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/tags?post=28601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}